Parion, Vertex deal

Parion granted Vertex exclusive, worldwide rights to a portfolio of epithelial sodium channel (ENaC) inhibitors to treat cystic fibrosis and other pulmonary diseases. The deal includes rights to Parion’s most advanced candidate, P-1037, which is in a Phase IIa trial to treat CF. The partners said they plan to investigate P-1037 in combination with Vertex’s lumacaftor ( VX-809) and Kalydeco ivacaftor to treat CF in patients with two copies of the F508del mutation. Vertex said the trial is expected to begin in early 2016. ...